 Beigene Ltd NASDAQ: BGNE shares are trading higher by 3.8 at 400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults with Waldenströms macroglobulinemia. Brutons tyrosine kinase BTK inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern, said Prof. 